• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The changing pattern of infection in neutropenic patients.

作者信息

Oppenheim B A

机构信息

Public Health Laboratory, Withington Hospital, West Didsbury, Manchester, UK.

出版信息

J Antimicrob Chemother. 1998 Jun;41 Suppl D:7-11. doi: 10.1093/jac/41.suppl_4.7.

DOI:10.1093/jac/41.suppl_4.7
PMID:9688447
Abstract

Over the past 20 years there has been a dramatic shift in the pattern of infection in neutropenic patients. During the 1970s Gram-negative organisms caused approximately 70% of all bacteraemias, but by the late 1980s the situation had reversed and approximately 70% of bacteraemias were due to Gram-positive organisms. The main contributors to this increase in Gram-positive infections have been the coagulase-negative staphylococci and the viridans streptococci. More recently, enterococci have emerged as significant pathogens in this patient group, and the development of glycopeptide resistance in the enterococci is of particular concern since this class of antibiotics is widely used in neutropenic patients. Among Gram-negative organisms, the emergence of resistance to fluoroquinolones, particularly in Escherichia coli, is a worrying feature which may lead to a reassessment of the use of quinolone prophylaxis in this setting.

摘要

相似文献

1
The changing pattern of infection in neutropenic patients.
J Antimicrob Chemother. 1998 Jun;41 Suppl D:7-11. doi: 10.1093/jac/41.suppl_4.7.
2
Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.革兰氏阳性菌中对抗菌药物的新出现耐药性。肠球菌、葡萄球菌和非肺炎链球菌。
Drugs. 1996;51 Suppl 1:6-12. doi: 10.2165/00003495-199600511-00004.
3
[Etiology of bacterial infections in febrile neutropenic patients: the role of the laboratory in the diagnosis].[发热性中性粒细胞减少患者细菌感染的病因:实验室在诊断中的作用]
Presse Med. 2004 Apr 10;33(7):460-6. doi: 10.1016/s0755-4982(04)98633-2.
4
Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.多重耐药革兰氏阳性病原体。当前微生物学模式的最新情况。
Drugs. 1997;54 Suppl 6:11-20. doi: 10.2165/00003495-199700546-00005.
5
Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.奎奴普丁/达福普汀对革兰氏阳性菌的活性:临床应用及治疗潜力。
J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. doi: 10.1093/jac/39.suppl_1.139.
6
Management of the febrile neutropenic patient.发热性中性粒细胞减少症患者的管理。
Int J Antimicrob Agents. 2005 Dec;26 Suppl 2:S120-2; discussion S133-40. doi: 10.1016/j.ijantimicag.2005.07.010. Epub 2005 Oct 21.
7
Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.中性粒细胞减少症癌症患者血流感染的病因、临床特征、抗菌药物耐药性和转归的变化。
Clin Microbiol Infect. 2013 May;19(5):474-9. doi: 10.1111/j.1469-0691.2012.03879.x. Epub 2012 Apr 24.
8
Nosocomial bloodstream infections: organisms, risk factors, and implications.医院获得性血流感染:病原体、危险因素及影响
Clin Infect Dis. 2000 Sep;31 Suppl 4:S139-43. doi: 10.1086/314078.
9
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).多利培南针对常见革兰氏阳性病原体的抗菌活性:一项全球监测研究(2003 - 2007年)的结果
Diagn Microbiol Infect Dis. 2009 Apr;63(4):440-6. doi: 10.1016/j.diagmicrobio.2009.01.019.
10
In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.通过2013年LEADER监测项目评估的利奈唑胺体外活性。
Diagn Microbiol Infect Dis. 2015 Apr;81(4):283-9. doi: 10.1016/j.diagmicrobio.2014.12.009. Epub 2014 Dec 30.

引用本文的文献

1
Exploring the mobilome and resistome of in a One Health context across two continents.在两大洲的“同一健康”背景下探索 中的可移动元件和抗药元件。
Microb Genom. 2022 Sep;8(9). doi: 10.1099/mgen.0.000880.
2
Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴一家转诊医院发热癌症患者血流感染分离株的微生物谱及耐药情况
Infect Drug Resist. 2018 Sep 18;11:1511-1519. doi: 10.2147/IDR.S168867. eCollection 2018.
3
Genetic relatedness and risk factor analysis of ampicillin-resistant and high-level gentamicin-resistant enterococci causing bloodstream infections in Tanzanian children.
坦桑尼亚儿童血流感染中氨苄西林耐药和高水平庆大霉素耐药肠球菌的遗传相关性及危险因素分析
BMC Infect Dis. 2015 Feb 28;15:107. doi: 10.1186/s12879-015-0845-8.
4
Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.急性髓系白血病患者中使用复方新诺明/黏菌素(COT/COL)与环丙沙星(CIP)进行抗生素预防的比较。
Support Care Cancer. 2015 May;23(5):1321-9. doi: 10.1007/s00520-015-2621-0. Epub 2015 Jan 24.
5
Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey.土耳其东南部单中心儿童发热性中性粒细胞减少症血流感染的细菌谱及抗菌药物敏感性模式。
Indian J Microbiol. 2012 Jun;52(2):203-8. doi: 10.1007/s12088-011-0210-6. Epub 2011 Aug 13.
6
Bacterial infection profiles in lung cancer patients with febrile neutropenia.肺癌合并发热性中性粒细胞减少症患者的细菌感染谱。
BMC Infect Dis. 2011 Jun 27;11:183. doi: 10.1186/1471-2334-11-183.
7
Microbial etiology of febrile neutropenia.发热性中性粒细胞减少症的微生物病因
Indian J Hematol Blood Transfus. 2010 Jun;26(2):49-55. doi: 10.1007/s12288-010-0029-z. Epub 2010 Sep 30.
8
Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients.感染概率评分、APACHE II 评分和卡诺夫斯基评分系统作为血液病-肿瘤患者血流感染发生的预测因子。
BMC Infect Dis. 2010 May 26;10:135. doi: 10.1186/1471-2334-10-135.
9
Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.静脉注射后口服大剂量环丙沙星单药治疗与头孢他啶加阿米卡星联合治疗作为粒细胞缺乏伴发热患者的初始经验性治疗。
Antimicrob Agents Chemother. 2000 Dec;44(12):3264-71. doi: 10.1128/AAC.44.12.3264-3271.2000.